• Beneficial effects of automated insulin delivery over one-year follow-up in real life for youths and adults with type 1 diabetes irrespective of patient characteristics. Diabetes Obes Metab. 2024 ici

• Twelve-month results of the ADAPT randomized controlled trial: Reproducibility and sustainability of advanced hybrid closed-loop therapy outcomes versus conventional therapy in adults with type 1 diabetes. Diabetes Obes Metabol 2023 ici

• Real world evidence of the efficacy of two Hybrid closed loop systems for children and adults with type 1 diabetes with some clinical warnings. Diabetes & Metabolism 2022 ici

• Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study, Lancet Diabetes Endocrinol 2022 ici

• Hybrid closed Loop improved glucose control compared to sensor-augmented pumps in outpatients with type 1 diabetes in real-life conditions with telehealth monitoring, Acta Diabetologica 2021  ici

• Insulin pump initiation in outpatient settings: when technology facilitates new healthcare organizations. Diabetes & Metabolism 2021  ici

• Pumps that predict and manage low blood glucose are superior to pumps with stand-alone CGM for reducing hypoglycaemia in type 1 diabetes patients in a real-world setting Diabetes & Metabolism 2021  ici

• Effects of remote care of patients with poorly controlled type 1 diabetes included in an experimental telemonitoring programme. Diabetes & Metabolism 2021  ici

• Histoire naturelle des cellules bêta au cours du diabète de type 1 : conséquences cliniques et possibilités thérapeutiques.  Médecine Maladies Métaboliques 2020.  ici

​

• Protéger sa peau avec un diabète. Livret DIAB-eCARE productions.  ici

​

​

​

​